我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
隶属于 Otsuka America, Inc.
相关临床试验
543
237 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
进行中（未招募）
227
41.8%
已完成
238
43.8%
Enrolling By Invitation
1
0.2%
尚未招募
9
1.7%
招募中
29
5.3%
终止
28
5.2%
Unknown
3
0.6%
撤回
8
1.5%
暂无批准数据
- Otsuka Pharmaceutical has filed a New Drug Application with the FDA for centanafadine, a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor for ADHD treatment. - Four pivotal Phase 3 trials demonstrated statistically significant efficacy across children, adolescents, and adults with ADHD compared to placebo. - The drug showed a favorable safety profile with low potential for abuse and dependence, potentially expanding treatment options for the 22.5 million Americans with ADHD.
